BioLife Solutions, Inc. (NASDAQ:BLFS) COO Greef Roderick De Sells 4,500 Shares

BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating) COO Greef Roderick De sold 4,500 shares of the stock in a transaction dated Wednesday, November 23rd. The shares were sold at an average price of $21.71, for a total transaction of $97,695.00. Following the completion of the sale, the chief operating officer now directly owns 79,719 shares in the company, valued at $1,730,699.49. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Greef Roderick De also recently made the following trade(s):

  • On Monday, November 21st, Greef Roderick De sold 9,500 shares of BioLife Solutions stock. The shares were sold at an average price of $21.63, for a total transaction of $205,485.00.
  • On Friday, November 18th, Greef Roderick De sold 1,500 shares of BioLife Solutions stock. The shares were sold at an average price of $22.13, for a total transaction of $33,195.00.
  • On Wednesday, November 16th, Greef Roderick De sold 1,500 shares of BioLife Solutions stock. The stock was sold at an average price of $23.21, for a total transaction of $34,815.00.
  • On Monday, November 14th, Greef Roderick De sold 20,000 shares of BioLife Solutions stock. The stock was sold at an average price of $23.86, for a total transaction of $477,200.00.
  • On Friday, October 7th, Greef Roderick De sold 8,552 shares of BioLife Solutions stock. The stock was sold at an average price of $22.69, for a total transaction of $194,044.88.
  • On Monday, October 3rd, Greef Roderick De sold 1,233 shares of BioLife Solutions stock. The stock was sold at an average price of $21.95, for a total transaction of $27,064.35.

BioLife Solutions Price Performance

NASDAQ BLFS traded up $0.06 during mid-day trading on Thursday, hitting $21.55. The company’s stock had a trading volume of 223,944 shares, compared to its average volume of 477,296. BioLife Solutions, Inc. has a 52-week low of $10.40 and a 52-week high of $45.40. The stock’s fifty day simple moving average is $22.03 and its two-hundred day simple moving average is $19.26. The company has a current ratio of 3.68, a quick ratio of 2.76 and a debt-to-equity ratio of 0.06.

Wall Street Analysts Forecast Growth

BLFS has been the topic of several analyst reports. Cowen decreased their price target on shares of BioLife Solutions to $29.00 in a research note on Monday, August 15th. Stephens cut their price objective on shares of BioLife Solutions to $31.00 in a report on Wednesday, November 16th. Finally, StockNews.com upgraded shares of BioLife Solutions to a “sell” rating in a report on Monday.

Institutional Trading of BioLife Solutions

A number of hedge funds have recently made changes to their positions in the company. Public Sector Pension Investment Board raised its stake in shares of BioLife Solutions by 1.0% during the second quarter. Public Sector Pension Investment Board now owns 56,525 shares of the medical equipment provider’s stock valued at $781,000 after purchasing an additional 565 shares during the period. Texas Permanent School Fund grew its position in shares of BioLife Solutions by 3.0% during the second quarter. Texas Permanent School Fund now owns 21,901 shares of the medical equipment provider’s stock worth $302,000 after buying an additional 642 shares in the last quarter. Macquarie Group Ltd. grew its position in shares of BioLife Solutions by 1.1% during the second quarter. Macquarie Group Ltd. now owns 73,437 shares of the medical equipment provider’s stock worth $1,014,000 after buying an additional 766 shares in the last quarter. Mutual of America Capital Management LLC grew its position in shares of BioLife Solutions by 18.7% during the second quarter. Mutual of America Capital Management LLC now owns 5,128 shares of the medical equipment provider’s stock worth $71,000 after buying an additional 808 shares in the last quarter. Finally, Jane Street Group LLC grew its position in shares of BioLife Solutions by 6.9% during the first quarter. Jane Street Group LLC now owns 13,377 shares of the medical equipment provider’s stock worth $304,000 after buying an additional 858 shares in the last quarter. Hedge funds and other institutional investors own 86.69% of the company’s stock.

BioLife Solutions Company Profile

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

See Also

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.